DDInter210 DDInter1752
Binimetinib, also known as _Mektovi_, is a potent and selective oral mitogen-activated protein kinase 1/2 (MEK 1/2) inhibitor which is combined with [Encorafenib].[A34275,L3335] On June 27, 2018, the Food and Drug Administration approved the combination of [Encorafenib] and binimetinib (BRAFTOVI and MEKTOVI, from Array BioPharma Inc.) in combination for patients with unresectable or metastatic melanoma with the BRAF V600E or V600K mutations, as detected by an FDA-approved test.
Drug-resistant bacteria, such as methicillin-resistant _Staphylococcus aureus_, vancomycin-resistant _Enterococcus faecium_, and penicillin-resistant _Streptococcus penumoniae_, represent a massive public health threat.[A199086, A199131] Tedizolid is a member of the oxazolidinone class of antibiotics, which includes the previously approved [linezolid] and is generally effective against multidrug-resistant Gram-positive bacteria. Tedizolid is indicated for the treatment of acute bacterial skin and skin structure infections (ABSSSI) and is generally more effective and more tolerable than [linezolid].[L11232, A199086, A199050] Tedizolid was approved by the FDA on June 20, 2014, for sale by Cubist Pharmaceuticals as tedizolid phosphate (SIVEXTRO®). This product is currently available as both an oral tablet and as a powder for intravenous injection.
Binimetinib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Delavirdine
Binimetinib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Troleandomycin
Binimetinib {u} may lead to a major life threatening interaction when taken with {v} Ramucirumab
Binimetinib {u} may lead to a major life threatening interaction when taken with {v} Zanubrutinib
Binimetinib may cause a moderate interaction that could exacerbate diseases when taken with Delavirdine
Binimetinib may cause a moderate interaction that could exacerbate diseases when taken with Troleandomycin
Binimetinib may lead to a major life threatening interaction when taken with Ramucirumab
Binimetinib may lead to a major life threatening interaction when taken with Zanubrutinib